Explore 3 Stock Ideas & Industry Insights Download Free Report
● Tuesday's reaction and season outlook are the next focus.
● It cut its 2026 adjusted EBITDA outlook to more than $40 million.
● Acute care revenue climbed strongly to $15.1 million.
● Hold means the analyst no longer expects outperformance.
● That was up about half from a year earlier.
● The extended-trading drop was steep.
● About three in four patients on placebo responded.
● The prior range was $100 million to $110 million.
● The adjusted operating loss was smaller than analysts expected.
● No company-specific news explained the gain.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…